Review
Copyright ©The Author(s) 2021.
World J Stem Cells. Aug 26, 2021; 13(8): 1030-1048
Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.1030
Table 3 The key parameter of clinical trials using transplantation of mesenchymal stem cells in treating ischemic stroke
Ref.
Country
Design
Type
Route
MSCs source
Sample size (cases)
Dose
How long
Follow-up
Auto or allo
MSCs
Control
(Mean)     
(Mean)
(Mean)
Savitz et al[137], 2011AmericaNon-RCTAcuteIVBM/Auto10NA100 × 1061-3 d0.5 yr
Lee et al[138], 2010South KoreaRCTAcuteIVPIC/Auto163650 × 1061 wk5 yr
Bhasin et al[151], 2011IndiaNon-RCTChronicIVBM/Auto4550-60 × 1068 wk24 wk
Bhasin et al[139], 2012IndiaNon-RCTChronicIVPIC/Auto121250-60 × 1063-24 mo0.5 yr
Bhasin et al[140], 2016IndiaNon-RCTChronicIVPIC/Auto202050-60 × 1063-24 mo0.5 yr
Chen et al[141], 2014ChinaRCTChronicStereotacticPB/Auto15153-8 × 1060.5-5 yr1 yr
Jiang et al[149], 2013ChinaNon-RCTNACatheterizationUC/Allo3NA20 × 10611-22 d0.5 yr
Laskowitz et al[14], 2018AmericaRCTAcuteIVUC/Allo10103.34 × 1063-9 d1 yr
Levy et al[142], 2019AmericaNon-RCTChronicIVNA/Allo15 and 20NANANA1 yr
Moniche et al[143], 2012SpainRCTSubacuteIAPIC/Auto1010159 × 1065-9 d0.5 yr
Prasad et al[144], 2014IndiaRCTSubacuteIVPIC/Auto6060280.5 × 1061-4 mo0.5 yr
Suárez-Monteagudo et al[150], 2009CubaNon-RCTNAIV BM/Auto3NANANA3 M
Vahidy et al[145], 2019AmericaRCTAcuteIVBM/Auto2530NA1-3 d2 yr
Zhang et al[146], 2019ChinaNon-RCTNAStereotacticFSC/Allo9NANA494 d2 yr
Díez-Tejedor et al[148], 2014SpainRCTAcuteIVAdipose/Allo2020NA0.5 mo2 yr
Feng et al[147], 2014ChinaNASubacuteStereotacticUC/Allo5050100 × 1060.5-1 mo0.25 yr
Jaillard et al[153], 2020FranceRCTSubacuteIVBM/Allo1615100-300 × 1063 wk24 mo
De Keyser[152], 2005South KoreaNon-RCTAcuteIVBM/Allo52550 × 1064-9 wk12 mo